BiotechTube

Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin

Pre-clinicalRecruiting
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Primary Hypercholesterolemiia

Conditions

Primary Hypercholesterolemiia, Mixed Dyslipidemia

Trial Timeline

Feb 12, 2025 → Jan 31, 2028

NCT ID
NCT06686615

About Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin

Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin is a pre-clinical stage product being developed by Daiichi Sankyo for Primary Hypercholesterolemiia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06686615. Target conditions include Primary Hypercholesterolemiia, Mixed Dyslipidemia.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (2)

NCT IDPhaseStatus
NCT07474649Phase 3Recruiting
NCT06686615Pre-clinicalRecruiting

Competing Products

20 competing products in Primary Hypercholesterolemiia

See all competitors
ProductCompanyStageHype Score
Unfractionated heparinSinopharmPre-clinical
22
azenosertibZentalis PharmaceuticalsPhase 2
44
Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved
77
REN001OnKure TherapeuticsPhase 1
25
Mavodelpar + PlaceboOnKure TherapeuticsPhase 2
44
REN001OnKure TherapeuticsPhase 2/3
57
SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, PlaceboSkye BiosciencePhase 2
44
Rituximab + Methotrexate + Cytarabine InjectionCelltrionPhase 2
52
Rituximab, lenalidomideCelltrionPhase 2
52
ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RISChugai PharmaceuticalPhase 3
77
CS-3150Daiichi SankyoPre-clinical
23
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
85
Combination of bempedoic acid and ezetimibeDaiichi SankyoPre-clinical
23
DS-8201a + T-DM1Daiichi SankyoPhase 3
77
Bempedoic acid and/or its fixed dose combination with ezetimibeDaiichi SankyoPre-clinical
23
Roxadustat + PlaceboAstellas PharmaPhase 3
77
Enzalutamide + ExemestaneAstellas PharmaPhase 2
52
Bocidelpar + PlaceboAstellas PharmaPhase 2
52
Methotrexate + Ibrutinib + TemozolomideSun PharmaceuticalPhase 2
52
Brinzolamide ophthalmic suspension + Azopt®Sun PharmaceuticalPhase 3
77

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85